MicroRNA and Their Potential Role in Conjunctival Disorders.


Journal

Korean journal of ophthalmology : KJO
ISSN: 2092-9382
Titre abrégé: Korean J Ophthalmol
Pays: Korea (South)
ID NLM: 8804513

Informations de publication

Date de publication:
10 2022
Historique:
received: 06 02 2022
accepted: 06 05 2022
pubmed: 22 8 2022
medline: 19 10 2022
entrez: 21 8 2022
Statut: ppublish

Résumé

MicroRNAs (miRNAs) are the small noncoding RNA molecules which regulate target gene expression posttranscriptionally. They are known to regulate key cellular processes like inflammation, cell differentiation, cell proliferation, and cell apoptosis across various ocular diseases. Due to their easier access, recent focus has been laid on the investigation of miRNA expression and their involvement in several conjunctival diseases. The aim of this narrative review is to provide understanding of the miRNAs and describe the current role of miRNAs as the mediators of the various conjunctival diseases. A literature search was made using PubMed, Scopus, and Web of Science databases for studies involving miRNAs in the conjunctival pathological conditions. Original articles in the last 10 years involving both human and animal models were included. Literature search retrieved 27 studies matching our criteria. Pertaining to the numerous literatures, there is a strong correlation between miRNA and the various pathological conditions that occur in the conjunctiva. miRNAs are involved in various physiological processes such as cell differentiation, proliferation, apoptosis, development, and inflammation by regulating various signaling pathways, genes, proteins, and mediators. Pterygium was the most studied conjunctival disease for miRNA involvement, whereas miRNA research in allergic conjunctivitis is still in its early stages. Our review provides deep insights into the various miRNAs playing an important role in the various conjunctival diseases. miRNAs do have the potential to serve as noninvasive biomarkers with diagnostic, prognostic, and therapeutic implications. However, multitudinous studies are required to validate miRNAs as the reliable biomarkers in conjunctival pathologies and its targeted therapy.

Identifiants

pubmed: 35989077
pii: kjo.2022.0010
doi: 10.3341/kjo.2022.0010
pmc: PMC9582503
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

452-462

Références

Pathog Dis. 2017 Mar 1;75(2):
pubmed: 28175294
Biomed Pharmacother. 2017 Oct;94:937-943
pubmed: 28810531
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
BMC Infect Dis. 2016 Feb 03;16:60
pubmed: 26842862
Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
Science. 2005 Jul 8;309(5732):310-1
pubmed: 15919954
Expert Rev Ophthalmol. 2014 Jun;9(3):185-204
pubmed: 25580155
Cell. 2007 Oct 5;131(1):146-59
pubmed: 17923094
Eye Contact Lens. 2019 May;45(3):208-211
pubmed: 30688676
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
pubmed: 15738415
Br J Ophthalmol. 2018 Dec;102(12):1728-1734
pubmed: 29511061
Mol Vis. 2018 Jul 23;24:485-494
pubmed: 30967746
Mol Vis. 2011 Jan 08;17:63-9
pubmed: 21245964
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Eye Vis (Lond). 2019 Jul 27;6:22
pubmed: 31372366
Sci Rep. 2020 Oct 14;10(1):17239
pubmed: 33057072
PLoS One. 2012;7(4):e35147
pubmed: 22536353
Nature. 2000 Feb 24;403(6772):901-6
pubmed: 10706289
Prog Retin Eye Res. 2009 Mar;28(2):87-116
pubmed: 19071227
Exp Eye Res. 2019 Jan;178:37-45
pubmed: 30243568
Exp Eye Res. 2013 Oct;115:189-98
pubmed: 23872359
Exp Eye Res. 2020 Aug;197:108047
pubmed: 32387379
Med Sci Monit. 2015 Jul 11;21:2000-7
pubmed: 26166175
Ital J Pediatr. 2013 Mar 14;39:18
pubmed: 23497516
J Allergy Clin Immunol. 2014 Apr;133(4):1065-74
pubmed: 24184144
Invest Ophthalmol Vis Sci. 2013 Aug 05;54(8):5169-75
pubmed: 23821202
FEBS Lett. 2020 Apr;594(7):1207-1217
pubmed: 31774554
Biomed Res Int. 2015;2015:604508
pubmed: 26380287
Ocul Surf. 2008 Jan;6(1):24-43
pubmed: 18264653
APMIS. 2016 Jun;124(6):475-86
pubmed: 27004972
BMC Biotechnol. 2018 Mar 16;18(1):16
pubmed: 29548320
Exp Eye Res. 2016 May;146:206-211
pubmed: 26995143
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Stem Cells. 2012 May;30(5):898-909
pubmed: 22367714
Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):523-31
pubmed: 22183793
Ocul Surf. 2013 Apr;11(2):133-8
pubmed: 23583047
Front Physiol. 2020 Nov 30;11:587381
pubmed: 33329037
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):509-15
pubmed: 17251443
Cell Cycle. 2015;14(12):1973-84
pubmed: 25565137
Curr Opin Cell Biol. 2009 Jun;21(3):470-9
pubmed: 19411171
Iran J Basic Med Sci. 2019 Aug;22(8):878-883
pubmed: 31579443
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Am J Ophthalmol. 2015 Aug;160(2):228-237.e2
pubmed: 25979679
J Oncol. 2020 Jul 3;2020:9160905
pubmed: 32714393
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Eur J Dermatol. 2015 Sep-Oct;25(5):457-62
pubmed: 26394757
Exp Eye Res. 2018 Apr;169:149-156
pubmed: 29360447
Infect Immun. 2011 Jan;79(1):499-511
pubmed: 20937763
PLoS Negl Trop Dis. 2013;7(3):e2117
pubmed: 23516655
Trends Plant Sci. 2016 Dec;21(12):1034-1044
pubmed: 27793495
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2362-70
pubmed: 23754433
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3723-30
pubmed: 27415790
J Bone Miner Res. 2009 May;24(5):816-25
pubmed: 19063684
Ocul Surf. 2021 Jan;19:115-127
pubmed: 32422284
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4205-12
pubmed: 27548891
Int J Cancer. 2007 Sep 1;121(5):1156-61
pubmed: 17487835
Ocul Surf. 2017 Oct;15(4):660-669
pubmed: 28483646
Exp Neurol. 2011 Jan;227(1):172-9
pubmed: 21035445
Melanoma Res. 2019 Oct;29(5):465-473
pubmed: 30932942
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2064-2071
pubmed: 31081880
Acta Ophthalmol. 2016 Aug;94(5):463-70
pubmed: 27009410
Nat Genet. 2003 Nov;35(3):215-7
pubmed: 14528307
Nat Genet. 2003 Nov;35(3):217-8
pubmed: 14528306
BMJ Open Ophthalmol. 2017 Aug 07;1(1):e000073
pubmed: 29354711
J Pharm Anal. 2019 Aug;9(4):217-226
pubmed: 31452959
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1511-7
pubmed: 17389479
Mol Vis. 2014 Jul 21;20:1048-56
pubmed: 25053875
Trends Biotechnol. 2015 Mar;33(3):180-8
pubmed: 25640199
Congenit Anom (Kyoto). 2014 Feb;54(1):12-21
pubmed: 24330020
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):8
pubmed: 32150250
Sci Transl Med. 2020 Dec 16;12(574):
pubmed: 33328332
Br J Ophthalmol. 2009 May;93(5):563-8
pubmed: 19098034

Auteurs

Nazmul Huda Syed (NH)

Department of Ophthalmology and Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Embong Zunaina (E)

Department of Ophthalmology and Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Shahidan Wan-Nazatul Shima (S)

Basic Science and Oral Biology Unit, School of Dental Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Malvika Sharma (M)

Department of Neuroscience, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Ismail Shatriah (I)

Department of Ophthalmology and Visual Science, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH